Virios Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Dogwood Therapeutics

09/05/2024 15:38

* Virios Therapeutics Inc  VIRI.OQ  reported a quarterly
adjusted
loss of 7 cents​​ per share for the quarter ended in March,
higher than the same quarter last year, when the company
reported EPS of -8 cents.  The lone analyst forecast for the
quarter was for a loss of 4 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Virios Therapeutics Inc's reported EPS for the quarter was
a
loss of 7 cents​.
    * Virios Therapeutics Inc shares had fallen by 10.5% this
quarter and lost 25.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 20% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Virios
Therapeutics Inc is $2.20 
This summary was machine generated from LSEG data May 9 at 02:37
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.04          -0.07          Missed
 Dec. 31 2023      -0.09          -0.06          Beat
 Sep. 30 2023      -0.09          -0.06          Beat
 Jun. 30 2023      -0.07          -0.08          Missed